These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

795 related items for PubMed ID: 30251544

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, Bénard F.
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [Abstract] [Full Text] [Related]

  • 3. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M, Umbricht CA, Schibli R, Müller C.
    Mol Pharm; 2018 Mar 05; 15(3):934-946. PubMed ID: 29400475
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
    Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, Niedermann G, Spohn SKB, Freitag MT, Grosu AL, Meyer PT, Gratzke C, Eder M, Zamboglou C, Eder AC.
    Theranostics; 2024 Jun 04; 14(6):2560-2572. PubMed ID: 38646643
    [Abstract] [Full Text] [Related]

  • 11. Multidose formulation of ready-to-use 177Lu-PSMA-617 in a centralized radiopharmacy set-up.
    Chakraborty S, Vimalnath KV, Chakravarty R, Sarma HD, Dash A.
    Appl Radiat Isot; 2018 Sep 04; 139():91-97. PubMed ID: 29734118
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, DiMagno SG, Babich JW.
    J Nucl Med; 2019 May 04; 60(5):656-663. PubMed ID: 30552199
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy.
    Chakraborty A, Mitra A, Tawate M, Sahoo S, Lad S, Rakshit S, Gaikwad S, Basu S, Shimpi H, Banerjee S.
    Cancer Biother Radiopharm; 2021 Oct 04; 36(8):682-692. PubMed ID: 34402687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
    Ling X, Latoche JD, Choy CJ, Kurland BF, Laymon CM, Wu Y, Salamacha N, Shen D, Geruntho JJ, Rigatti LH, Windish HP, Langton-Webster B, Berkman CE, Anderson CJ.
    Mol Imaging Biol; 2020 Apr 04; 22(2):274-284. PubMed ID: 31321650
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
    Escudero-Castellanos A, Ocampo-García B, Ferro-Flores G, Santos-Cuevas C, Morales-Ávila E, Luna-Gutiérrez M, Isaac-Olivé K.
    Nucl Med Commun; 2019 Mar 04; 40(3):278-286. PubMed ID: 30763290
    [Abstract] [Full Text] [Related]

  • 20. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
    Lee BS, Kim MH, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim HS, Kim MH, Kil HS, Han SJ, Lee YJ, Lee KC, Lim SM, Chi DY.
    Mol Cancer Ther; 2021 Dec 04; 20(12):2410-2419. PubMed ID: 34725194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.